IMR Press / FBL / Volume 21 / Issue 5 / DOI: 10.2741/4438

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Bacterial resistance to antimicrobial peptides: an evolving phenomenon

Show Less
1 Pos-Graduacao da Faculdade de Medicina, Campus Universitario Darcy Ribeiro, Universidade de Brasilia, Asa Norte, Brasília, DF, Brazil
2 S-Inova, Programa de Pos-Graduacao em Biotecnologia, Universidade Catolica Dom Bosco, 79117-900 Campo Grande, MS, Brazil
3 Department of Biochemistry, School of Biological Sciences, College of Agriculture and Natural Sciences, University of Cape Coast, Cape Coast, Ghana
4 Centro de Analises Proteomicas e Bioquimicas, Programa de Pos-Graduacao em Ciencias Genomicas e Biotecnologia, Universidade Catolica de Brasilia, 70719-100 Brasília, DF, Brazil
Front. Biosci. (Landmark Ed) 2016, 21(5), 1013–1038;
Published: 1 June 2016

Bacterial resistance to conventional antibiotics is currently a real problem all over the world, making novel antimicrobial compounds a real research priority. Some of the most promising compounds found to date are antimicrobial peptides (AMPs). The benefits of these drugs include their broad spectrum of activity that affects several microbial processes, making the emergence of resistance less likely. However, bacterial resistance to AMPs is an evolving phenomenon that compromises the therapeutic potential of these compounds. Therefore, it is mandatory to understand bacterial mechanisms of resistance to AMPs in depth, in order to develop more powerful AMPs that overcome the bacterial resistance response.

Antimicrobial peptides
Back to top